{"podcast":{"title":"Sydney News Today | 2 Min News | The Daily News Now!","slug":"sydney-news-today-2-min-news-the-daily-news-now-7568669","podcast_index_feed_id":7568669,"rss_url":"https://feeds.fastcast.ai/seattle-storm-the-daily-news-now.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/podcasts/seattle-storm-the-daily-news-now.jpg","author":"The Daily News Now!","episode_count":2780,"summary":"Hosted by Corey with the Story, Sydney News Today delivers daily coverage of everything happening in Sydney with fast, focused updates on local news, government, business, public safety, weather, and the stories shaping the city. From major developments to neighborhood updates, the show keeps you informed on what matters most across Sydney. Each short episode highlights what matters most—including key updates, local trends, and stories shaping the city—produced by AI for speed, consistency, and clarity. Part of The Daily News Now network, Sydney News Today is built for listeners who want reliable local news coverage in a quick, easy-to-digest format. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-07-28T16:20:11.638189+00:00","page_url":"https://stenobird.com/podcast/sydney-news-today-2-min-news-the-daily-news-now-7568669"},"episode":{"title":"Amplia Therapeutics Leadership Shift | Sydney News","slug":"amplia-therapeutics-leadership-shift-sydney-news","published_at":"2026-06-30T06:18:26+00:00","page_url":"https://stenobird.com/podcast/sydney-news-today-2-min-news-the-daily-news-now-7568669/amplia-therapeutics-leadership-shift-sydney-news","show_page_url":"https://stenobird.com/podcast/sydney-news-today-2-min-news-the-daily-news-now-7568669","url":"https://api.fastcast.ai/audio/c2ebf147-ee68-410c-92bc-3f145faff367.mp3","audio_url":"https://api.fastcast.ai/audio/c2ebf147-ee68-410c-92bc-3f145faff367.mp3","summary":"Amplia Therapeutics is shaking up its leadership with Jane Bell AM stepping in as chairman, timed perfectly with breakthrough clinical data for its drug narmafotinib — showing a 36% response rate and over 11 months median survival in advanced pancreatic cancer patients, without added toxicity. Backed by recent Nature Medicine research validating its FAK-targeting approach, the company is poised for FDA discussions, fast-track and orphan drug designations, and scaling manufacturing — all while exploring applications in ovarian cancer, pulmonary fibrosis, and as a companion therapy for KRAS inhibitors. This isn’t just a boardroom change — it’s the launchpad for turning science into market reality. Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/5a2e5d65e4cff479","meta_description":"Amplia Therapeutics is shaking up its leadership with Jane Bell AM stepping in as chairman, timed perfectly with breakthrough clinical data for its drug n…","key_points":[],"chapters":[],"topics":[],"duration_seconds":135,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/sydney-news-today-2-min-news-the-daily-news-now-7568669/episodes/amplia-therapeutics-leadership-shift-sydney-news/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/sydney-news-today-2-min-news-the-daily-news-now-7568669/amplia-therapeutics-leadership-shift-sydney-news.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}